Aileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Significant Increase in Short Interest

Aileron Therapeutics, Inc. (NASDAQ:ALRN) saw a large growth in short interest in September. As of September 30th, there was short interest totalling 297,800 shares, a growth of 15.8% from the September 15th total of 257,100 shares. Currently, 1.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 66,100 shares, the short-interest ratio is currently 4.5 days.

Institutional Trading of Aileron Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Texas Capital Bank Wealth Management Services Inc lifted its stake in shares of Aileron Therapeutics by 65.9% in the 1st quarter. Texas Capital Bank Wealth Management Services Inc now owns 26,171 shares of the company’s stock valued at $174,000 after acquiring an additional 10,398 shares during the last quarter. Warberg Asset Management LLC bought a new stake in Aileron Therapeutics during the 2nd quarter worth $86,000. Nantahala Capital Management LLC increased its holdings in Aileron Therapeutics by 82.1% in the 2nd quarter. Nantahala Capital Management LLC now owns 464,367 shares of the company’s stock worth $1,286,000 after purchasing an additional 209,367 shares in the last quarter. Finally, University of Texas Texas AM Investment Management Co. bought a new position in Aileron Therapeutics in the second quarter valued at about $4,925,000. Institutional investors own 90.89% of the company’s stock.

Aileron Therapeutics Stock Up 2.8 %

Shares of ALRN stock opened at $3.69 on Wednesday. The business has a fifty day simple moving average of $2.83 and a 200 day simple moving average of $3.38. The company has a market cap of $79.76 million, a P/E ratio of -1.16 and a beta of 2.35. Aileron Therapeutics has a twelve month low of $1.01 and a twelve month high of $7.42.

Aileron Therapeutics (NASDAQ:ALRN) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.20). As a group, equities research analysts anticipate that Aileron Therapeutics will post -1.41 earnings per share for the current fiscal year.

About Aileron Therapeutics

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).